Profile data is unavailable for this security.
About the company
Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the Company's proprietary ingredients, commercialized as Tru Niagen, directly to consumers and distributors. The Ingredients segment develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Ingredients segment provides Niagen in ingredient form to its strategic partners. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.
- Revenue in USD (TTM)83.17m
- Net income in USD-3.53m
- Incorporated2008
- Employees106.00
- LocationChromadex Corp10900 Wilshire Blvd, Suite 600LOS ANGELES 90024United StatesUSA
- Phone+1 (310) 388-6706
- Fax+1 (302) 421-5753
- Websitehttps://chromadex.com/default.aspx
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Design Therapeutics Inc | 0.00 | -58.67m | 180.78m | 57.00 | -- | 0.6707 | -- | -- | -1.05 | -1.05 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -19.44 | -- | -19.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Candel Therapeutics Inc | 0.00 | -37.37m | 185.98m | 42.00 | -- | 30.68 | -- | -- | -1.29 | -1.29 | 0.00 | 0.2037 | 0.00 | -- | -- | 0.00 | -75.90 | -- | -93.79 | -- | -- | -- | -- | -- | -- | -38.49 | 0.7674 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Century Therapeutics Inc | 1.37m | -133.47m | 186.75m | 152.00 | -- | 0.8052 | -- | 136.31 | -2.22 | -2.22 | 0.0227 | 2.74 | 0.0034 | -- | -- | 9,013.16 | -33.17 | -- | -35.08 | -- | -- | -- | -9,742.41 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| Acrivon Therapeutics Inc | 0.00 | -64.12m | 187.73m | 58.00 | -- | 1.27 | -- | -- | -2.88 | -2.88 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -44.11 | -- | -46.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
| Trevi Therapeutics Inc | 0.00 | -33.57m | 188.77m | 25.00 | -- | 2.56 | -- | -- | -0.338 | -0.338 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -34.47 | -47.39 | -38.08 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0017 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -30.01m | 193.10m | 10.00 | -- | 1.70 | -- | -- | -0.5080 | -0.5080 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -19.39 | -36.79 | -22.08 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1182 | -- | -- | -- | 39.47 | -- | -- | -- |
| Chromadex Corp | 83.17m | -3.53m | 194.89m | 106.00 | -- | 6.70 | -- | 2.34 | -0.047 | -0.047 | 1.11 | 0.3852 | 1.54 | 2.66 | 10.01 | 784,594.30 | -6.54 | -42.11 | -10.08 | -65.14 | 60.98 | 59.68 | -4.24 | -30.64 | 1.88 | -- | 0.0007 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -33.08m | 195.13m | 140.00 | -- | 25.23 | -- | -- | -1.29 | -1.29 | 0.00 | 0.1534 | 0.00 | -- | -- | 0.00 | -87.80 | -- | -140.92 | -- | -- | -- | -- | -- | -- | -28.75 | 0.6695 | -- | -- | -- | -11.06 | -- | -- | -- |
| 2Seventy Bio Inc | 71.20m | -223.22m | 198.42m | 274.00 | -- | 0.9565 | -- | 2.79 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Akebia Therapeutics Inc | 187.23m | -43.03m | 201.21m | 167.00 | -- | -- | -- | 1.07 | -0.2213 | -0.2213 | 0.9726 | -0.1301 | 0.7454 | 1.34 | 8.43 | 1,121,108.00 | -17.13 | -37.42 | -24.39 | -56.00 | 83.44 | 69.13 | -22.98 | -82.25 | 1.31 | -4.82 | 10.44 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| AVITA Medical Inc | 50.70m | -44.82m | 203.30m | 207.00 | -- | 6.24 | -- | 4.01 | -1.76 | -1.76 | 1.99 | 1.26 | 0.5336 | 1.48 | 8.39 | 244,913.00 | -47.18 | -- | -53.79 | -- | 85.43 | -- | -88.41 | -- | 6.64 | -19.61 | 0.5591 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| Codexis Inc | 74.23m | -65.13m | 203.91m | 174.00 | -- | 2.57 | -- | 2.75 | -0.9412 | -0.9412 | 1.07 | 1.12 | 0.4039 | 5.92 | 4.34 | 426,632.20 | -35.43 | -17.13 | -43.38 | -20.23 | 82.29 | 77.29 | -87.73 | -37.04 | 3.63 | -- | 0.2617 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| Prelude Therapeutics Inc | 0.00 | -125.55m | 204.89m | 128.00 | -- | 0.7447 | -- | -- | -1.88 | -1.88 | 0.00 | 5.01 | 0.00 | -- | -- | 0.00 | -56.37 | -47.21 | -61.52 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 207.29m | 49.00 | -- | 4.67 | -- | 2,559.17 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
Data as of Jul 03 2024. Currency figures normalised to Chromadex Corp's reporting currency: US Dollar USD
13.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.03m | 4.01% |
| Tieton Capital Management LLCas of 31 Mar 2024 | 3.02m | 4.00% |
| ICONIQ Capital LLCas of 31 Mar 2024 | 1.30m | 1.72% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 894.42k | 1.18% |
| Millennium Management LLCas of 31 Mar 2024 | 584.28k | 0.77% |
| Geode Capital Management LLCas of 31 Mar 2024 | 561.06k | 0.74% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 383.70k | 0.51% |
| GAMCO Asset Management, Inc.as of 31 Mar 2024 | 263.85k | 0.35% |
| Susquehanna Financial Group LLLPas of 31 Mar 2024 | 254.98k | 0.34% |
| Jane Street Capital LLCas of 31 Mar 2024 | 228.24k | 0.30% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
